- Home
- VINP vs PHAR Comparison
VINP vs PHAR Comparison
Compare VINP & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VINP | PHAR |
|---|---|---|
| Founded | 2009 | 1988 |
| Country | Brazil | Netherlands |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 807.6M | 1.1B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | VINP | PHAR |
|---|---|---|
| Price | $13.01 | $17.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $13.50 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 46.6K | 26.8K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | ★ 4.60% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.50 | 0.00 |
| Revenue | $180,689,571.00 | ★ $362,274,000.00 |
| Revenue This Year | $67.12 | $25.19 |
| Revenue Next Year | $15.14 | $4.47 |
| P/E Ratio | ★ $25.99 | $3,002.99 |
| Revenue Growth | ★ 100.47 | 26.78 |
| 52 Week Low | $8.66 | $7.50 |
| 52 Week High | $13.37 | $18.30 |
Technical Indicators
Market Signals| Indicator | VINP | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 60.25 | 51.55 |
| Support Level | $12.77 | $16.55 |
| Resistance Level | $13.21 | $18.30 |
| Average True Range (ATR) | 0.29 | 0.80 |
| MACD | -0.04 | -0.07 |
| Stochastic Oscillator | 47.95 | 41.02 |
Price Performance
Historical ComparisonAbout VINP Vinci Partners Investments Ltd.
Vinci Compass Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.